These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 8318875

  • 1. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
    Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH, Poirier MC.
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC.
    Cancer Res; 1990 Apr 15; 50(8):2256-60. PubMed ID: 2180564
    [Abstract] [Full Text] [Related]

  • 3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov 15; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 4. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S.
    Cancer Res; 1992 Jan 01; 52(1):149-53. PubMed ID: 1727376
    [Abstract] [Full Text] [Related]

  • 5. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
    Poirier MC, Egorin MJ, Fichtinger-Schepman AM, Yuspa SH, Reed E.
    IARC Sci Publ; 1988 Jan 01; (89):313-20. PubMed ID: 3058599
    [Abstract] [Full Text] [Related]

  • 6. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC.
    J Clin Invest; 1986 Feb 01; 77(2):545-50. PubMed ID: 3944268
    [Abstract] [Full Text] [Related]

  • 7. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
    Blommaert FA, Michael C, Terheggen PM, Muggia FM, Kortes V, Schornagel JH, Hart AA, den Engelse L.
    Cancer Res; 1993 Dec 01; 53(23):5669-75. PubMed ID: 8242622
    [Abstract] [Full Text] [Related]

  • 8. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F.
    Cancer Res; 1990 Dec 15; 50(24):7887-94. PubMed ID: 2253228
    [Abstract] [Full Text] [Related]

  • 9. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 10. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Motzer RJ, Reed E, Perera F, Tang D, Shamkhani H, Poirier MC, Tsai WY, Parker RJ, Bosl GJ.
    Cancer; 1994 Jun 01; 73(11):2843-52. PubMed ID: 7514956
    [Abstract] [Full Text] [Related]

  • 11. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ.
    Clin Cancer Res; 2001 Aug 01; 7(8):2205-12. PubMed ID: 11489793
    [Abstract] [Full Text] [Related]

  • 12. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
    Fisch MJ, Howard KL, Einhorn LH, Sledge GW.
    Clin Cancer Res; 1996 Jun 01; 2(6):1063-6. PubMed ID: 9816268
    [Abstract] [Full Text] [Related]

  • 13. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP.
    Clin Cancer Res; 2000 Aug 01; 6(8):3260-70. PubMed ID: 10955812
    [Abstract] [Full Text] [Related]

  • 14. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
    Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC.
    Cancer Res; 1987 Feb 01; 47(3):718-22. PubMed ID: 3802077
    [Abstract] [Full Text] [Related]

  • 15. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 Jul 01; 50(1):100-4. PubMed ID: 8349150
    [Abstract] [Full Text] [Related]

  • 16. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
    Poirier MC, Reed E, Shamkhani H, Tarone RE, Gupta-Burt S.
    Environ Health Perspect; 1993 Mar 01; 99():149-54. PubMed ID: 8319613
    [Abstract] [Full Text] [Related]

  • 17. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
    Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC.
    Proc Natl Acad Sci U S A; 1987 Jul 01; 84(14):5024-8. PubMed ID: 3110781
    [Abstract] [Full Text] [Related]

  • 18. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E.
    Carcinogenesis; 1991 Jul 01; 12(7):1253-8. PubMed ID: 2070490
    [Abstract] [Full Text] [Related]

  • 19. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Jul 01; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
    Reed E, Gupta-Burt S, Litterst CL, Poirier MC.
    Carcinogenesis; 1990 Dec 01; 11(12):2117-21. PubMed ID: 1979937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.